APA (7th ed.) Citation

Pfob, A., Surovtsova, I., Kokh, D. B., Smetanay, K., Schneeweiss, A., Zivanovic, O., . . . Morakis, P. (2025). Use of bevacizumab for patients with International Federation of Gynecology and Obstetrics stage IIIB to IV epithelial ovarian cancer undergoing primary debulking surgery and its association with oncologic outcomes: A Cancer Registry study. International journal of gynecological cancer, 36(1), . https://doi.org/10.1016/j.ijgc.2025.102770

Chicago Style (17th ed.) Citation

Pfob, André, Irina Surovtsova, Daria B. Kokh, Katharina Smetanay, Andreas Schneeweiss, Oliver Zivanovic, Georg Sauer, and Philipp Morakis. "Use of Bevacizumab for Patients with International Federation of Gynecology and Obstetrics Stage IIIB to IV Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery and Its Association with Oncologic Outcomes: A Cancer Registry Study." International Journal of Gynecological Cancer 36, no. 1 (2025). https://doi.org/10.1016/j.ijgc.2025.102770.

MLA (9th ed.) Citation

Pfob, André, et al. "Use of Bevacizumab for Patients with International Federation of Gynecology and Obstetrics Stage IIIB to IV Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery and Its Association with Oncologic Outcomes: A Cancer Registry Study." International Journal of Gynecological Cancer, vol. 36, no. 1, 2025, https://doi.org/10.1016/j.ijgc.2025.102770.